| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Etoposide (formerly VP-16, VP-16213; Toposar; VePesid; Lastet; EPEG), a chemotherapeutic drug used for the treatments of various cancers, is a semisynthetic derivative of the naturally occuring podophyllotoxin which inhibits DNA synthesis via topoisomerase II inhibitory activity. The mandrake root, Podophyllum peltatum, is used to extract etoposide. It binds to topoisomerase II and inhibits it, giving it strong anticancer properties. Etoposide inhibits DNA replication and transcription, causes apoptosis in cells, and accumulates single- or double-strand breaks in DNA molecules by ligating the broken DNA molecules. The G2 and S phases of the cell cycle are when etoposide primarily acts.
| Targets |
Topoisomerase II
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Enzyme Assay |
Nuclei are isolated and nuclear extracts are prepared. The percentage of decatenation obtained is used to calculate the activity of topoisomerase II. The substrate is tritiated kinoplast DNA (KDNA 0.22 μg). After 30 minutes of incubation at 37 °C, etoposide and topoisomerase II are stopped with 100 μg/mL of proteinase K and 1% sodium dodecyl sulfate (SDS). We obtain the percentages of topoisomerase II decatenation and inhibition by etoposide.
|
||
| Cell Assay |
Cells treated with etoposide are removed from the dish and diluted into culture dishes in an amount sufficient to produce 20–200 colonies. The phosphate-buffered saline (PBS) solution contains 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA). Methanol-acetic acid is used to fix the cultures after 12 days, crystal violet is used for staining, and colonies with more than 50 cells are scored. Unless otherwise specified, standard errors are usually less than 15% of the mean value.
|
||
| Animal Protocol |
|
||
| References |
[1]. J Natl Cancer Inst . 1988 Dec 7;80(19):1526-33. [2]. J Dermatol Sci . 2000 Nov;24(2):126-33. [3]. Cancer Res . 1983 Apr;43(4):1592-7. [4]. Cancer Chemother Pharmacol . 2001 Oct;48(4):327-32. [5]. Cancer Chemother Pharmacol . 1998;41(2):93-7. [6]. Cancer . 1998 Dec 1;83(11):2400-7. [7]. Gan To Kagaku Ryoho . 1991 Jun;18(7):1155-61. |
| Molecular Formula |
C29H32O13
|
|---|---|
| Molecular Weight |
588.56
|
| Exact Mass |
588.18
|
| Elemental Analysis |
C, 59.18; H, 5.48; O, 35.34
|
| CAS # |
33419-42-0
|
| Related CAS # |
117091-64-2
|
| Appearance |
White to off-white solid powder
|
| SMILES |
C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
|
| InChi Key |
VJJPUSNTGOMMGY-MRVIYFEKSA-N
|
| InChi Code |
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
|
| Chemical Name |
(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
|
| Synonyms |
Demethyl Epipodophyllotoxin Ethylidine Glucoside; epipodophyllotoxin. US brand names: Toposar. VePesid. Foreign brand name: Lastet. Abbreviation: EPEG Code names: VP16; VP16213
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 0.5 mg/mL (0.85 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 6: 30% Propylene glycol , 5% Tween 80 , 65% D5W: 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6991 mL | 8.4953 mL | 16.9906 mL | |
| 5 mM | 0.3398 mL | 1.6991 mL | 3.3981 mL | |
| 10 mM | 0.1699 mL | 0.8495 mL | 1.6991 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02678299 | Active Recruiting |
Drug: PREBEN | Malignant Lymphoma | University of Aarhus | February 2016 | Phase 1 Phase 2 |
| NCT00632853 | Active Recruiting |
Drug: etoposide Drug: cisplatin |
Lung Cancer | Alliance for Clinical Trials in Oncology |
March 2008 | Phase 3 |
| NCT01873326 | Active Recruiting |
Drug: Etoposide Drug: Mesna |
Germ Cell Tumors | Memorial Sloan Kettering Cancer Center |
June 2013 | Phase 2 |
| NCT04622228 | Active Recruiting |
Drug: Etoposide Drug: Carboplatin |
Carcinoma, Small Cell Lung | Hoffmann-La Roche | December 16, 2020 | Phase 2 |
| NCT02512926 | Active Recruiting |
Drug: Etoposide Drug: Carfilzomib |
Relapsed Leukemia Refractory Leukemia |
Stanford University | February 16, 2016 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA